CA - Aurinia Pharmaceuticals Inc. (AUPH) Q2 2024 Earnings Call Transcript
2024-08-01 13:52:05 ET
Aurinia Pharmaceuticals, Inc. (AUPH)
Q2 2024 Earnings Conference Call
August 01, 2024, 08:30 ET
Company Participants
Andrea Christopher - Head, Corporate Communications & IR
Peter Greenleaf - President, CEO & Director
Greg Keenan - Chief Medical Officer
Joe Miller - CFO
Conference Call Participants
Joseph Schwartz - Leerink Partners
Stacy Ku - TD Cowen
Ed Arce - H.C. Wainwright & Co.
Presentation
Operator
Good day, ladies and gentlemen. Welcome to Aurinia Pharmaceuticals Second Quarter 2024 Earnings Call. [Operator Instructions]. As a reminder, this conference is being recorded. I would like to turn the conference over to your host, Andrea Christopher, Head of Corporate Communications and Investor Relations for Aurinia Pharmaceuticals. Thank you. You may begin.
Andrea Christopher
Thank you, operator. And thank you to everyone for joining today's call and webcast. Joining me on the call this morning are Peter Greenleaf, Aurinia's Chief Executive Officer; Joe Miller, our Chief Financial Officer, and Dr. Greg Keenan, our Chief Medical Officer. Today, we will review and discuss Aurinia's 2024 second quarter financial and operational results as communicated in the company's press release issued this morning.
The company also filed its quarterly financial statements on Form 10-Q this morning. For more information, please refer to Aurinia's filings with the US Securities and Exchange Commission and Canadian securities authorities, which are also available on Aurinia's website at auriniapharma.com.
During today's call, Aurinia may make forward-looking statements based on current expectations. These forward-looking statements are subject to a number of significant risks and uncertainties, and actual results may differ materially. For discussion of factors that could affect Aurinia's future financial results and business. Please refer to the disclosures in Aurinia's press release, it's quarterly report on Form 10-Q and its annual report on Form 10-K and all of its recent filings with the US Securities and Exchange Commission and Canadian securities authority.
Please note that all statements made during today's call are current as of today, Thursday, August 1, 2024, unless otherwise noted and are based upon information currently available to us, except as required by law, Aurinia assumes no obligation to update any such statements.
Now let me turn the call over to Aurinia's President and CEO, Peter Greenleaf, Peter....
Aurinia Pharmaceuticals, Inc. (AUPH) Q2 2024 Earnings Call Transcript